Kardigan — Third Quarter 2026 Earnings Summary

Kardigan, Inc. reported completing enrollment in Cohort 2 of the Phase 2b KINSHIP-DCM trial for its drug danicamtiv, with topline data expected in the second quarter of 2027. The company also finished enrollment in the Phase 2b KATALYST-AV trial for ataciguat, targeting aortic stenosis, and expects topline data for that study in the second half of 2027. Kardigan holds a cash position of $591.4 million as of September 30, 2026, which supports continued clinical advancement across its three programs, including the ongoing Phase 2 KARDINAL-ASH trial for tonlamarsen.